BioVie Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioVie (BIVI).

Price Target Range — 2 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingOutperform# Analysts2Avg. Consensus PT$400Upside to Avg. PT+28471.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 1, 2024	ThinkEquity	Ashok Kumar	Initiate	Buy	$300
Nov 30, 2023	Oppenheimer	Jay Olson	PT Cut	Outperform	$1200→$500

Analyst Ratings News

PRO
ThinkEquity Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $3

ThinkEquity analyst Ashok Kumar initiates coverage on BioVie (NASDAQ:BIVI) with a Buy rating and announces Price Target of $3.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on BioVie, Lowers Price Target to $5

Oppenheimer analyst Jay Olson maintains BioVie (NASDAQ:BIVI) with a Outperform and lowers the price target from $12 to $5.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates BioVie (NASDAQ:BIVI) with a Overweight and maintains $11 price target.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates BioVie (NASDAQ:BIVI) with a Overweight and maintains $11 price target.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates BioVie (NASDAQ:BIVI) with a Overweight and maintains $11 price target.

Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on BioVie, Maintains $12 Price Target

Oppenheimer analyst Jay Olson reiterates BioVie (NASDAQ:BIVI) with a Outperform and maintains $12 price target.

Benzinga Newsdesk

BioVie Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

BioVie Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
ThinkEquity Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $3

PRO
Oppenheimer Maintains Outperform on BioVie, Lowers Price Target to $5

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PRO
Oppenheimer Reiterates Outperform on BioVie, Maintains $12 Price Target

People Also Watch

People Also Watch

BioVie Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

BioVie Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROThinkEquity Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $3

PROOppenheimer Maintains Outperform on BioVie, Lowers Price Target to $5

PROCantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PROCantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PROCantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PROOppenheimer Reiterates Outperform on BioVie, Maintains $12 Price Target

People Also Watch

People Also Watch

PRO
ThinkEquity Initiates Coverage On BioVie with Buy Rating, Announces Price Target of $3

PRO
Oppenheimer Maintains Outperform on BioVie, Lowers Price Target to $5

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PRO
Cantor Fitzgerald Reiterates Overweight on BioVie, Maintains $11 Price Target

PRO
Oppenheimer Reiterates Outperform on BioVie, Maintains $12 Price Target